Avicanna announced it has entered into an agreement to supply medical cannabis products to patients in the UK with Astral Health.
Avicanna (TSX:AVCN,OTCQX:AVCNF) announced it has entered into an importation and distribution agreement to supply cannabis-based medical products to patients in the United Kingdom with Astral Health, the operating subsidiary of the LYPHE Group.
As quoted in the press release:
We look forward to the opportunity to provide access to our cannabis-based medicinal formulations to a population and medical community that is seeing increased demand for quality evidence-based products, such as our proprietary research-backed formulations. Both the Astral and Avicanna teams are aligned on the long-term vision and more importantly are qualified to provide the medical community in the United Kingdom with safe, effective and superior cannabinoid-based solutions, education and training,” stated Aras Azadian, Chief Executive Officer.
Dean Friday, Chief Executive Officer of LYPHE, commented “We are very proud to be partnering with Avicanna in bringing their products to the UK market. Avicanna are market-leaders in terms of product quality, and their research-backed formulations give the company a distinct advantage in the UK market”.